59989-18-3C#Cc1c[nH]c(=O)[nH]c1=OJOZGNYDSEBIJDH-UHFFFAOYSA-N59989-18-3DTXSID10208696CHEMBL355200CHEBI:177783Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Eniluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU).
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
VerwendenPotent inactivator of Dihydropyrimidine dehydrogenase (DPD).
Wird geladen…